This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Abivax Presents Positive Obefazimod...
Tech Clinical trial results

Abivax Presents Positive Obefazimod Data at ECCO

Analysis based on 8 articles · First reported Feb 21, 2026 · Last updated Feb 21, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The positive clinical and preclinical data for Abivax's obefazimod are expected to positively impact Abivax's stock price and investor confidence. The promising results for inflammatory bowel disease, particularly Crohn's disease, suggest a significant market opportunity for Abivax.

Biotechnology Pharmaceuticals
Event Summary

Abivax presented novel preclinical and clinical data for its lead drug candidate, obefazimod, at the European Crohn s and Colitis Organization's 21st Annual Congress. The data highlighted obefazimod's anti-fibrotic activity in preclinical models, a favorable safety and tolerability profile in Phase 3 ABTECT induction trials, and rapid onset of symptomatic relief in patients with moderately to severely active ulcerative colitis. Biomarker data also indicated upregulation of miR-124 and reduction of inflammatory cytokines. These findings reinforce Abivax's confidence in obefazimod's potential for inflammatory bowel disease, with upcoming Phase 3 maintenance trial readout in Q2 2026 and Phase 2b ENHANCE-CD trial readout in Q4 2026.

Key Actions
100 Abivax Presented novel preclinical and clinical data for obefazimod European Crohn s and Colitis Organization
Entities Involved
stock
Abivax
Abivax announced positive preclinical and clinical data for its lead drug candidate, obefazimod, at the ECCO 2026 congress. These findings highlight obefazimod's anti-fibrotic potential in Crohn's disease, favorable safety profile, and rapid symptomatic relief, strengthening confidence in its development for inflammatory bowel disease.
Importance 100 Sentiment 70
per
Marc de Garidel
As CEO of Abivax, Marc de Garidel expressed strong confidence in obefazimod's unique profile and potential across ulcerative colitis and Crohn's disease, based on the robust data presented at ECCO 2026.
Importance 50 Sentiment 60
per
Fabio Cataldi
As Chief Medical Officer of Abivax, Fabio Cataldi highlighted the compelling preclinical evidence of obefazimod's anti-fibrotic activity and its favorable safety profile, positioning it as a potential oral therapy for unmet needs in inflammatory bowel disease.
Importance 50 Sentiment 60
per
Silvio Danese
Professor Silvio Danese, Director of the Gastroenterology and Digestive Endoscopy Unit of the IRCCS San Raffaele Hospital, found the data on obefazimod encouraging, noting its potential for long-term disease control and bowel function preservation in inflammatory bowel disease patients.
Importance 40 Sentiment 60
ngo
European Crohn s and Colitis Organization
The European Crohn s and Colitis Organization hosted its 21st Annual Congress, where Abivax presented 22 abstracts detailing the preclinical and clinical data for obefazimod.
Importance 30 Sentiment 0
priv
IRCCS San Raffaele Hospital
The IRCCS San Raffaele Hospital is where Professor Silvio Danese, who commented on the obefazimod data, serves as Director of the Gastroenterology and Digestive Endoscopy Unit.
Importance 10 Sentiment 0
Relationships
Marc de Garidel related ↔ Abivax
Fabio Cataldi related ↔ Abivax
Silvio Danese related ↔ IRCCS San Raffaele Hospital
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.